Human natural killer cells in health and disease

Pediatric Blood and Cancer

Volumn 49, Issue 5, 2007, Pages 615-623

  Shereck, Evan ^a   Satwani, Prakash ^a   Morris, Erin ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Function; Natural killer cell immunology; Review

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; LECTIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; CELLULAR IMMUNITY; CHILD; CHILDHOOD LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NATURAL KILLER CELL; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; IMMUNOLOGY; TRANSPLANTATION;

CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL;

EID: 35148869539     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21158     Document Type: Review

References (82)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-2438.
2. Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935-1947.
3. Timonen T, Ortaldo JR, Herberman RB. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 1981;153:569-582.
4. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971;134:1513-1528.
5. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med 1971;134:83-102.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
7. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 1987;165:1212-1217.
8. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
9. Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4486.
10. Leibson PJ. Signal transduction during natural killer cell activation: Inside the mind of a killer. Immunity 1997;6:655-661.
11. Shibuya A, Kojima H, Shibuya K, et al. Enrichment of interleukin-2- responsive natural killer progenitors in human bone marrow. Blood 1993;81:1819-1826.
12. Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood 1992;80:2182-2187.
13. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87:2632-2640.
14. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-780.
15. Fehniger TA, Caligiuri MA. Interleukin 15: Biology and relevance to human disease. Blood 2001;97:14-32.
16. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998;92:3647-3657.
17. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
18. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
19. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359-393.
20. Lazetic S, Chang C, Houchins JP, et al. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 1996;157:4741-4745.
21. Plougastel B, Jones T, Trowsdale J. Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene. Immunogenetics 1996;44:286-291.
22. Glienke J, Sobanov Y, Brostjan C, et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics 1998;48:163-173.
23. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
24. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
25. O'Neill AF, Satwani P, Guttmann S, et al. Increased expression of natural killer (NK) cell activating receptor NK G2D ligands on pediatric solid and hematologic malignancies: Potential role of NK cellular immunotherapy. Pediatr Blood Cancer 2005 (abstract); 45: P.A.047.
26. Sivori S, Vitale M, Morelli L, et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997;186:1129-1136.
27. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-2072.
28. Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-796.
29. Maki G, Krystal G, Dougherty G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: Possible role of ICAM-3 and CD44. Leukemia 1998;12:1565-1572.
30. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-383.
31. Moretta L, Bottino C, Pende D, et al. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005;100:7-13.
32. Pao LI, Sumaria N, Kelly JM, et al. Functional analysis of granzyme M and its role in immunity to infection. J Immunol 2005;175:3235-3243.
33. Berthou C, Marolleau JP, Lafaurie C, et al. Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 1995;86:3500-3506.
34. Spaeny-Dekking EH, Kamp AM, Froelich CJ, et al. Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors. Blood 2000;95:1465-1472.
35. Andoniou CE, van Dommelen SL, Voigt V, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 2005;6:1011-1019.
36. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-3151.
37. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-1756.
38. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
39. Wallin RP, Screpanti V, Michaelsson J, et al. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol 2003;33:2727-2735.
40. Oshimi Y, Oda S, Honda Y, et al. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996;157:2909-2915.
41. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-169.
42. Meehan KR, Verma UN, Cahill R, et al. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: Investigation of dose level with clinical correlates. Bone Marrow Transplant 1997;20:643-651.
43. Miller JS, Tessmer-Tuck J, Pierson BA, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 1997;3:34-44.
44. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992;79:517-526.
45. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
46. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
47. Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 1995;16:283-288.
48. Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89:3951-3959.
49. Margolin KA, Van Besien K, Wright C, et al. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant 1999;5:36-45.
50. Toh HC, McAfee SL, Sackstein R, et al. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - A phase II study. Bone Marrow Transplant 2000;25:19-24.
51. Cheung NV, Lazarus H, Miraldi FD, et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 1992;10:671-672.
52. Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204.
53. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-193.
54. Handgretinger R, Anderson K, Lang R et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-267.
55. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-2180.
56. Bauer M, Reaman GH, Hank JA, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995;75:2959-2965.
57. Favrot MC, Michon J, Floret D, et al. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation. Pediatr Hematol Oncol 1990;7:275-284.
58. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-5239.
59. Meloni G, Foa R, Capria S, et al. IL-2 for the treatment of acute leukemias. Leukemia 1992;6:28-30.
60. Ribeiro RC, Rill D, Roberson PK, et al. Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 1993;72:623-628.
61. Schwinger W, Klass V, Benesch M, et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 2005;16:1199-1206.
62. Sievers EL, Lange BJ, Sondel PM, et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group. J Clin Oncol 1998;16:914-919.
63. Lange BJ, Smith FO, Dinndorf PA, et al. Outcomes in CCG-2961, a Children's Cancer Group Phase III trial for untreated acute myeloid leukemia (AML). Blood 2005 (abstract); 106:169.
64. Mackall C, Hakim F, Velardi A. The lympho-hematopoietic system: effector and target of graft-versus-host disease. In: Ferrara J, Cooke K, Deeg H, editors. Graft vs. host disease. New York: Marcel Dekker; 2004.
65. Velardi A, Ruggeri L, Moretta A, et al. NK cells: A lesson from mismatched hematopoietic transplantation. Trends Immunol 2002;23:438-444.
66. Ruggeri L, Capanni M, Mancusi A, et al. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005;14:203-206.
67. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
68. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644-650.
69. Stockerl-Goldstein KE, Blume KG, Allogeneic HCT for adult patients with AML. In: Blume KG, Forman SJ, Appelbaum FR, editors. Hematopoietic cell transplantation. Malden: Blackwell Science; 2004. 1025-1039.
70. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004;63:204-211.
71. Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005;106:4370-4376.
72. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: Immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005;105:4135-4142.
73. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005;105:4878-4884.
74. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002;100:3825-3827.
75. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003;123:323-326.
76. Bornhauser M, Schwerdtfeger R, Martin H, et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004;103:2860-2861; author reply 2862.
77. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-819.
78. Morishima Y, Yabe T, Inoko H, et al. Clinical significance of killer IG-like receptor (KIR) on acute GVHD, rejection and leukemia relapse in patients transplanted non-T cell depleted marrow from unrelated donors; roles of inhibitory KIR epitope matching and activating KIR genotype. Blood 2003 (abstract); 102:526a.
79. Elmaagacli AH, Ottinger H, Koldehoff M, et al. Reduced risk of molecular and haematological relapse in patients with CML after KIR mismatched haematopoietic stem cell transplantation. Bone Marrow Transplant 2004 (abstract); 33:S59.
80. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005;105:2594-2600.
81. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005;7:16-22.
82. Elmaagacli AH, Ottinger H, Koldehoff M, et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005;79:1741-1747.